Anti irf7 antibody

Manufactured by Cell Signaling Technology

The Anti-IRF7 antibody is a tool for detecting the presence and abundance of the transcription factor IRF7 (Interferon Regulatory Factor 7) in biological samples. It can be used in various research applications to study the expression and regulation of IRF7, a key regulator of type I interferon response.

Automatically generated - may contain errors

Lab products found in correlation

Anti tbk1 antibody, by Cell Signaling Technology (1 mentions) Anti ha antibody, by Cell Signaling Technology (1 mentions) Anti α tubulin antibody t5168, by Merck Group (1 mentions) Anti myc tag antibody, by Cell Signaling Technology (1 mentions) Anti sting antibody, by Cell Signaling Technology (1 mentions) Anti irf3 antibody, by Cell Signaling Technology (1 mentions) Anti rictor antibody, by Cell Signaling Technology (1 mentions) Anti vinculin antibody sc 25336, by Santa Cruz Biotechnology (1 mentions) Anti rbx1, by Cell Signaling Technology (1 mentions) Anti c myc antibody, by Cell Signaling Technology (1 mentions) Anti flag antibody, by Merck Group (1 mentions)

2 protocols using anti irf7 antibody

Comprehensive Antibody Optimization Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

All antibodies were used at a 1:1,000 dilution in TBS with 0.1% Tween 20 detergent buffer with 5% non-fat milk for Western blotting. Anti-Myc-Tag antibody (2278), anti-HA antibody (3724), anti-Phospho-Akt Substrate (RXRXXpS*/pT*) antibody (10001), anti-p-AKT (Ser473; 4060), anti- anti-p-p70 S6 Kinase (Thr389; 9234), anti-p-S6 Ribosomal Protein (Ser240/244; 5364), anti-p-4EBP1 (Thr37/46; 2855), pIRF3 antibody (Ser386; 37829), anti-IRF3 antibody (4302), anti-IRF7 antibody (4920), anti- anti-p-TBK1 (Ser172; 5483), anti-TBK1 antibody (51872), anti-STING antibody (13647), anti-c-Myc antibody (18583), anti-RSK1/2/3 antibody (9347), anti-Rictor antibody (9476), anti-Rbx1 (11922), anti-Skp1 antibody (12248), anti-rabbit IgG, HRP-linked antibody (7074), and anti-mouse IgG, HRP-linked antibody (7076) were obtained from Cell Signaling Technology. Anti-cyclin E antibody (sc-198), anti-β-catenin antibody (sc-59737), anti-c-Jun antibody (sc-45), anti-GST antibody (sc-459), anti-Cul1 (sc-11384), and anti-vinculin antibody (sc-25336) were obtained from Santa Cruz Biotechnology. Polyclonal anti-Flag antibody (F-7425), monoclonal anti-Flag antibody (F-3165, clone M2), and anti-α-tubulin antibody (T-5168) were obtained from Sigma-Aldrich. Anti-BUD13 antibody (20163-1-AP) and anti-Fbw7 antibody (28424-1-AP) were obtained from Proteintech.

Chen J., Zhang X., Tan X, & Liu P. (2023). Somatic gain-of-function mutations in BUD13 promote oncogenesis by disrupting Fbw7 function. The Journal of Experimental Medicine, 220(10), e20222056.

+ Open protocol

+ Expand

IFN-β Activation by IRF7 Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols

The method has been described in detail elsewhere (Zhang et al., 2020b (link)). HEK293T cells were cotransfected with a mixture of the IFN-β-firefly luciferase reporter plasmid, the pRL-TK-Renilla luciferase plasmid, and the pCDNA3-IRF7 plasmid. Cells were incubated for 24 h and were then either left untreated or infected with Sendai virus (20 hemagglutination units/well) for another 24 h. Reporter activity was measured with the Dual-Luciferase Reporter Assay System. Firefly luciferase activity was normalized against Renilla luciferase activity. IRF7 expression levels were measured by Western blotting (anti-IRF7 antibody: Cell Signaling; anti-FLAG antibody: Sigma-Aldrich).

Zhang Q., Matuozzo D., Le Pen J., Lee D., Moens L., Asano T., Bohlen J., Liu Z., Moncada-Velez M., Kendir-Demirkol Y., Jing H., Bizien L., Marchal A., Abolhassani H., Delafontaine S., Bucciol G., Bayhan G.I., Keles S., Kiykim A., Hancerli S., Haerynck F., Florkin B., Hatipoglu N., Ozcelik T., Morelle G., Zatz M., Ng L.F., Lye D.C., Young B.E., Leo Y.S., Dalgard C.L., Lifton R.P., Renia L., Meyts I., Jouanguy E., Hammarström L., Pan-Hammarström Q., Boisson B., Bastard P., Su H.C., Boisson-Dupuis S., Abel L., Rice C.M., Zhang S.Y., Cobat A, & Casanova J.L. (2022). Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. The Journal of Experimental Medicine, 219(8), e20220131.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!